Physician profile
Sergio Penaherrera
NPI 1538258744
$4,614.73
in general payments reported to CMS, 2019-2025
31 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,188 · 2020: $586 · 2021: $929 · 2022: $765 · 2023: $464 · 2024: $478 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $990.63 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $642.30 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $506.58 | 2019-2023 | Farxiga |
| Amgen INC. | $476.58 | 2019-2024 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $329.31 | 2019-2024 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $199.94 | 2019-2023 | |
| Medtronic, INC. | $152.54 | 2021-2023 | Minimed 780g, Minimed 770g |
| Dexcom, INC. | $148.35 | 2021-2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $129.51 | 2021-2024 | |
| Abbvie INC. | $121.93 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.98 | 2019-2024 | Jardiance |
| Corcept Therapeutics | $97.09 | 2021-2023 | Korlym |
| Nevro Corp. | $89.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $68.67 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $60.27 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.14 | 2021 | |
| Tandem Diabetes Care, INC. | $47.92 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $47.15 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $46.87 | 2020-2024 | |
| Insulet Corporation | $45.33 | 2021-2023 | Omnipod |
| Xeris Pharmaceuticals, INC. | $43.08 | 2023 | Gvoke Hypopen |
| Mannkind Corporation | $33.31 | 2019-2021 | |
| Edwards Lifesciences Corporation | $31.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.84 | 2019 | |
| Gilead Sciences, INC. | $18.05 | 2024 | |
| Nestle Healthcare Nutrition INC. | $17.22 | 2023 | |
| Glaxosmithkline, LLC. | $16.21 | 2020 | |
| Radius Health, INC. | $13.53 | 2019 | |
| Allergan, INC. | $13.12 | 2020 | |
| Amarin Pharma, INC. | $12.87 | 2019 | |
| Ge Healthcare | $11.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergio Penaherrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.